Menu
Back to Journals » Neuropsychiatric Disease and Treatment » Volume 9
Two cases of Alzheimer's disease showing deterioration of behavioral and psychological symptoms of dementia induced by switching from rivastigmine to donepezil
Authors Kimura T, Takamatsu J
Received 4 September 2012
Accepted for publication 15 October 2012
Published 28 December 2012 Volume 2013:9 Pages 49—53
DOI https://doi.org/10.2147/NDT.S37688
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Takemi Kimura, Junichi Takamatsu
Division of Clinical Research, National Hospital Organization Kikuchi Hospital, Koshi, Kumamoto, Japan
Abstract: Rivastigmine, galantamine, and memantine, in addition to donepezil, which has been on the market over 10 years, have been available for the treatment of Alzheimer's disease (AD) since 2011 in Japan, leading a new stage in the medical treatment of AD. We studied two AD patients showing sudden deterioration of behavioral and psychological symptoms of dementia (BPSD) associated with switching from rivastigmine to donepezil after the clinical trial of rivastigmine. In the patients, rivastigmine seemed to be more beneficial than donepezil for the control of BPSD. Although It was not obvious whether their different responses to the two cholinesterase inhibitors were due to the different pharmacological profiles, ie, the presence of inhibition of butyrylcholinesterase in rivastigmine, a particular cholinesterase inhibitor might be more effective in particular AD cases. Further investigations are needed to confirm the difference, and to identify the measures for selecting the most appropriate medication for each AD patient.
Keywords: rivastigmine, donepezil, cholinesterase inhibitors, switching, behavioral and psychological symptoms of dementia, neuropsychiatric inventory, Japanese, Alzheimer's disease
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.